Moser, Kenneth M.
August 1959
Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p253
Academic Journal
1. In the doses used, the toxic potential of fibrinolysin is limited primarily to temperature elevation. In the absence of prophylactic medication, a febrile reaction occurred in 44.4 per cent of the patients, and could be correlated only with the presence of extensive thrombotic material. 2. Changes in coagulation factors and parameters were minimal at the dosage levels used, with fibrinogen being affected to the greatest extent. The changes were not of sufficient degree to impair the integrity of the coagulative mechanism. No hemorrhagic phenomena occurred in any patients, including 29 who were simultaneously' receiving anticoagulant drugs. 3. Plasma fibrinolytic activity was significantly enhanced at all dosage levels, with degree and duration of activity being dependent upon dosage.


Related Articles

  • Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors. Gould, W.R.; Leadley, R.J. // Current Pharmaceutical Design;Nov2003, Vol. 9 Issue 28, p2337 

    Coronary heart disease (CHD) is the leading cause of mortality and morbidity in the United States. Currently, there are approximately 12 million Americans with CHD, which is most frequently caused by atherosclerosis. The thrombotic complications of atherosclerosis, such as acute coronary...

  • Discovery and Pre-clinical Development of Antithrombotics from Hematophagous Invertebrates. Ledizet, Michel; Harrison, Lisa M.; Koski, Raymond A.; Cappello, Michael // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jan2005, Vol. 3 Issue 1, p1 

    Bloodfeeding (hematophagous) parasites have evolved effective means of inhibiting mammalian thrombosis, thereby facilitating the acquisition and digestion of a bloodmeal. To date, specific inhibitors of coagulation and platelet function have been identified from numerous invertebrate species,...

  • TREATMENT OF CHRONIC THROMBOEMBOLISM WITH ARVIN, ORAL FIBRINOLYTICS AND STANDARD ANTICOAGULANTS. Kounis, Nicholas G.; Evans, W. Howel // Vascular Surgery;Mar/Apr1977, Vol. 11 Issue 2, p68 

    In five patients suffering from recurrent deep venous thrombosis and pulmonary embolism, a therapeutic combination was applied including Arvin, Fearnley's regime and standard anticoagulants. In two patients complete remission of the disease seemed to he achieved during the following two years....

  • VENOUS THROMBOSIS IN CHILDHOOD. Balas, P.; Tripolitis, A.; Charocopos, E.; Mandalaki, R. T. // Angiology;Dec1976, Vol. 27 Issue 12, p730 

    Venous thrombosis in childhood is an extremely rare condition. The etiologic factors in childhood are different than in the adult. Generalized infection seems to play the main etiologic role, and for this reason antibiotic treatment is usually necessary. Anticoagulant treatment is mandatory;...

  • Routine Stocking Therapy after Deep Venous Thrombosis: A Clinical Dilemma. Ginsberg, Jeffrey S. // Annals of Internal Medicine;8/17/2004, Vol. 141 Issue 4, p314 

    The article presents information on the stocking therapy after deep venous thrombosis. The post-thrombotic syndrome is one of the most common and frustating chronic conditions that physicians encounter. Patients with acute venous thrombosis have pain and swelling of the affected extremity caused...

  • EXPERIENCE WITH THE USE OF HUMAN FIBRINOLYSIN. Villavicencio, J. Leonel; Warren, Richard // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p263 

    1. Experiences with the clinical and experimental administration of plasmin are reported. 2. Of the methods for the assay of plasma fibrinolytic activity which were tested (fibrin plate, euglobulin on fibrin clot, euglobulin on benzoyl arginine methyl ester (BAME), plasma on BAME, and whole...

  • Lumbrokinase -- A Potent and Stable Fibrin--Specific Plasminogen Activator. Verma, Mahendra Kumar; Pulicherla, K. K. // International Journal of Bio-Science & Bio-Technology;Jun2011, Vol. 3 Issue 2, p57 

    Cardio and cerebrocascular disorders lead to about 26 million deaths every year around the world. Cardio and cerebrovaccular disorders have not only high mortality rate across the globe but also leading to subsequent complication such as thrombolysis could favorably influence the outcome of such...

  • CLINICAL OBSERVATIONS IN THROMBOEMBOLIC DISEASE TREATED WITH FIBRINOLYSIN. Moser, Kenneth M. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p319 

    Describes experiences in the treatment of venous and arterial thrombotic disease using fibrinolysin. Ability of the anticoagulant drugs to provide a satisfactory degree of protection against the development of thrombosis; Factors determining response to fibrinolysin; Dependency of the therapy...

  • Characterization of the coagulation system in healthy dolphins: the coagulation factors, natural anticoagulants, and fibrinolytic products. Tibbs, Rita F.; Elghetany, M. Tarek; Tran, Lethu T.; van Bonn, W.; Romano, T.; Cowan, Daniel F. // Comparative Clinical Pathology;Nov2005, Vol. 14 Issue 2, p95 

    In dolphins, blood pooling and acidosis from lack of oxygenation with prolonged underwater stay are not associated with intravascular clotting as it would be in terrestrial mammals, while shed blood clots promptly, and intravascular clots form after death. This intriguing physiologic adaptation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics